NewAmsterdam Pharma Company N.V. (NAMS)
NasdaqGM · USD · Healthcare · Biotechnology
$19.53 (-0.91%) as of
Key statistics
- Market cap
- 2.28B
- Forward P/E
- -12.75
- EPS (TTM)
- -2.14
- Dividend yield
- 0.00%
- 52-week range
- 19.13 – 42.21
- Beta
- 0.10
- Revenue (TTM)
- 7.12M
- Profit margin
- 0.00%
- Analyst target
- $49.84
- Volume
- 1.56M
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Naarden, Netherlands
- Employees
- 100
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.